SRx Health Solutions Files 8-K on Delisting Concerns
Ticker: SRXH · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1471727
Sentiment: bearish
Topics: delisting, listing-standards, financial-statements
TL;DR
SRx Health Solutions might be delisted - 8-K filed.
AI Summary
SRx Health Solutions, Inc. filed an 8-K on October 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and also filed financial statements and exhibits. The company's principal executive offices are located at 12400 Race Track Road, Tampa, Florida.
Why It Matters
This filing indicates potential issues with SRx Health Solutions' continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event that can lead to severe consequences for a company's stock.
Key Players & Entities
- SRx Health Solutions, Inc. (company) — Registrant
- October 14, 2025 (date) — Earliest event reported
- October 17, 2025 (date) — Filing date
- 12400 Race Track Road, Tampa, Florida 33626 (address) — Principal Executive Offices
- Delaware (jurisdiction) — State of Incorporation
- 001-40477 (commission_file_number) — SEC File Number
- 83-4284557 (ein) — IRS Employer Identification No.
FAQ
What specific listing rule or standard has SRx Health Solutions, Inc. failed to satisfy?
The filing does not specify the exact listing rule or standard that SRx Health Solutions, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 14, 2025.
Where are the principal executive offices of SRx Health Solutions, Inc. located?
The principal executive offices of SRx Health Solutions, Inc. are located at 12400 Race Track Road, Tampa, Florida 33626.
What is the SEC file number for SRx Health Solutions, Inc.?
The SEC file number for SRx Health Solutions, Inc. is 001-40477.
What other items are included in this 8-K filing besides the notice of delisting?
In addition to the notice of delisting or failure to satisfy a continued listing rule or standard, this 8-K filing also includes Financial Statements and Exhibits.
Filing Stats: 775 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-10-17 15:37:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value share SRXH NYSE American
- $4 million — company to have stockholders' equity of $4 million or more if the listed company has repor
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 15KB
- 0001493152-25-018441.txt ( ) — 238KB
- srxh-20251014.xsd (EX-101.SCH) — 3KB
- srxh-20251014_lab.xml (EX-101.LAB) — 33KB
- srxh-20251014_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2025 SRx Health Solutions, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40477 83-4284557 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 12400 Race Track Road Tampa , Florida 33626 (Address of Principal Executive Offices) (Zip Code) (Registrant's Telephone Number, Including Area Code): (212) 896-1254 N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value share SRXH NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On October 14, 2025, SRx Health Solutions, Inc, a Delaware corporation. (the "Company") received a written notice (the "Notice") from the NYSE American LLC (the "NYSE American") indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide ("Section 1003(a)(ii)"). Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.. The Notice has no immediate effect on the listing or trading of the Company's common stock and the common stock will continue to trade on the NYSE American under the symbol "SRXH." Additionally, the Notice does not result in the immediate delisting of the Company's common stock from the NYSE American. The Company is subject to the procedures and requirements of Section 1009 of the Company Guide. The procedures and requirements of Section 1009 of the NYSE American Company Guide, which could, among other things, result in the initiation of delisting proceedings, unless the Company cures the deficiency in a timely manner. NYSE American may also accelerate delisting action in the event that the Company's common stock trades at levels viewed by the Staff to be abnormally low. The Company has until November 13, 2025, to submit a plan of actions it has taken or will take to regain compliance with the Exchange's continued listing standards by July 14, 2026. The Company intends to regain compliance with the NYSE American's continued listing standards by undertaking a measure or measures that are for the best interests of the Company and its shareholders. The Company's receipt of the Notice does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission. The Company is actively engaged in discussions with the NYSE American and is developing plans to regain compliance with the NYSE American's continued listing standards within the cure period. As required under NYSE American rules, the Company issued a press release on October 17, 2025, announcing that it had received the Notice. A copy of the press release announcing these events is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein. Item 9.01 Financial (d) Exhibits. Exhibits Description 99.1 Press Release dated October 17, 2025. 104 Cover Page Interactive Data File (Embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SRx Health Solutions, Inc. By: /s/ Carolina Martinez